Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00) Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10) Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09) Incidence and management of interstitial lung disease caused by T-DXd (14:54) Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45) Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39) Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12) Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09) Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35) CME information and select publications

Ver todos los episodios